It is made available under a CC-BY-NC-ND 4.0 International license .

Optimal COVID-19 testing strategy on limited resources

- 2 Onishi Tatsuki^{1,2,3}¶, Honda Naoki^{4, 5,6}¶* Yasunobu Igarashi^{7,8}*
- 3

1

- ⁴ ¹ Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University,
- 5 Yoshidakonoecho, Sakyo, Kyoto, Japan
- 6 ² Department of Anesthesiology and Pain Clinic, Juntendo University Shizuoka Hospital, Izunokuni,
- 7 Shizuoka, Japan
- ⁸ ³ Department of Anaesthesiology, Tokyo Metropolitan Bokutoh Hospital, Kotobashi, Sumida, Tokyo, Japan
- ⁹ ⁴ Laboratory for Data-driven Biology, Graduate School of Integrated Sciences for Life, Hiroshima University,
- 10 Higashihiroshima, Hiroshima, Japan
- ⁵ Theoretical Biology Research Group, Exploratory Research Center on Life and Living Systems
- 12 (ExCELLS), National Institutes of Natural Sciences, Okazaki, Aichi, Japan
- ⁶ Laboratory of Theoretical Biology, Graduate School of Biostudies, Kyoto University, Yoshidakonoecho,
- 14 Sakyo, Kyoto, Japan
- ¹⁵ ⁷ E2D3.org, izumi-cho, Kokubunji, Tokyo, Japan
- ⁸ Center for Research on Assistive Technology for Building a New Community, Nagoya Institute of
- 17 Technology, Nagoya, Aichi, Japan
- 18
- 19 * Corresponding author
- 20 E-mail: yasunobu.igarashi@gmail.com
- 21
- 22 ***** Co-corresponding author
- 23 E-mail: nhonda@hiroshima-u.ac.jp
- 24
- ²⁵ These authors contributed equally to this work.

It is made available under a CC-BY-NC-ND 4.0 International license .

27 Abstract

28 The last three years have been spent combating COVID-19, and governments have been seeking optimal 29 solutions to minimize the negative impacts on societies. Although two types of testing have been performed 30 for this-follow-up testing for those who had close contact with infected individuals and mass-testing of 31 those with symptoms—the allocation of resources has been controversial. Mathematical models such as the 32 susceptible, infectious, exposed, recovered, and dead (SEIRD) model have been developed to predict the 33 spread of infection. However, these models do not consider the effects of testing characteristics and resource 34 limitations. To determine the optimal testing strategy, we developed a testing-SEIRD model that depends on 35 testing characteristics and limited resources. In this model, people who test positive are admitted to the 36 hospital based on capacity and medical resources. Using this model, we examined the infection spread 37 depending on the ratio of follow-up and mass-testing. The simulations demonstrated that the infection 38 dynamics exhibit an all-or-none response as infection expands or extinguishes. Optimal and worst follow-up 39 and mass-testing combinations were determined depending on the total resources and cost ratio of the two 40 types of testing. Furthermore, we demonstrated that the cumulative deaths varied significantly by hundreds 41 to thousands of times depending on the testing strategy, which is encouraging for policymakers. Therefore, 42 our model might provide guidelines for testing strategies in the cases of recently emerging infectious 43 diseases.

44

It is made available under a CC-BY-NC-ND 4.0 International license .

46 **1 Introduction**

47 The Coronavirus disease 2019 (COVID-19) emerged in Wuhan, China, raising concerns regarding global healthcare [1,2]. By April 2020, the COVID-19 Alpha variant pandemic had infected 5.5 million people, and 48 350,000 people had died, owing to its high aerosol transmission ability and the lack of specific treatment in 49 the early stages [3]. Medical resources in hospitals were primarily used to treat COVID-19 patients [1,2]. As 50 51 of April 2020, approximately 10% of hospital beds, or 10-20% of ICU beds were occupied with COVID-19 52 care [3-5]. Moreover, in May 2020, the COVID-19 Beta variant emerged. The society needed to be updated about the variant of concern (VOC) such as the Beta, Gamma, Delta, and Omicron variants every time a new 53 54 variant emerged [6-8].

55 To minimize the number of deaths, society must be aware of the advantages and disadvantages of 56 COVID-19 testing [9]. From an individual perspective, testing has advantages in that asymptomatic infected 57 individuals can be detected and prepared for symptomatic treatment, whereas from a societal perspective, 58 testing prevents secondary infections, expecting a reduction in the number of deaths [10–12]. The Alpha 59 variant pandemic in April 2020, in which no specific treatment was established and testing characteristics, 60 that is, sensitivity and specificity, were unknown, illustrates the drawbacks of testing, particularly in the early pandemic stage. From an individual perspective, the testing result had no impact on medical care 61 62 because there was no specific treatment, but from a societal perspective, testing was performed aimlessly, and people were uncertain about the testing outcomes, resulting in the wastage of medical and human 63 64 resources. Therefore, policymakers must consider the testing characteristics when determining the volume of testing at each early stage of an emerging VOC. 65

The testing policies to minimize the number of deaths in the early stages of the COVID-19 Alpha 66 67 variant pandemic were controversial [7,10,11,13,15–20], and the controversy was centered on the two 68 extreme policies for balancing the medical supply and demand: mass-testing and no-testing [21]. According to the mass-testing policy, everyone must be tested for public health, regardless of their symptoms [22–24]. 69 The mass-testing policy assumes that testing and hospitalization of asymptomatic patients are important for 70 71 reducing the overall death rate even in the absence of a specific treatment. Conversely, the no-testing policy 72 claims that testing must be limited to symptomatic patients [21]. According to the no-testing policy, 73 asymptomatic patients cannot expect to benefit from mass-testing in the absence of a specific treatment. 74 Despite differences in these two policies' assumptions, they both support testing on people with symptoms. 75 However, these approaches disagree regarding the size of the tested asymptomatic population.

What testing strategy is most practical for minimizing the number of deaths? There are two testing strategies for people without symptoms: follow-up-testing-dominant strategy, which follows up and tests the exposed population, and mass-dominant testing strategy, which randomly tests the infected population. Uncertainty about how follow-up and mass-testing of asymptomatic populations will affect the number of deaths and determine the worst and optimal outcomes, particularly in the early stages of emerging VOC in the future, remains a challenge [7,10,11,13,15–20].

It is made available under a CC-BY-NC-ND 4.0 International license .

82 In this study, we developed a testing-SEIRD model, aiming to evaluate a testing strategy that 83 combines follow-up and mass-testing in terms of minimizing the number of deaths during the early stages of 84 the emerging VOC. The testing-SEIRD model considers the testing characteristics, testing strategies, hospitalized subpopulation, and the amount of medical resource [25]. Using this model, we examined the 85 86 optimal and worst testing strategies under the assumption that medical resources are both infinite and finite. 87 We found that the optimal testing strategy significantly depends on the cost ratio between mass and follow-88 up testing. Therefore, this study provides insights into how to minimize the number of deaths in the absence 89 of a specific treatment during the early stages of a pandemic.

It is made available under a CC-BY-NC-ND 4.0 International license .

91 **2 Model**

92 To examine the impact of testing on the infection population dynamics, we developed a novel model by

93 incorporating a hospitalized subpopulation, testing strategy, and testing characteristics into the classical

94 SEIRD model. Generally, the subpopulation susceptible dynamics, exposed, infectious, recovered, and dead

. . .

95 people best summarize the SEIRD model (Fig. 1A) as follows:

$$\frac{dS}{dt} = -\frac{bIS}{N}, \#(2.1)$$
$$\frac{dE}{dt} = \frac{bIS}{N} - gE, \#(2.2)$$
$$\frac{dI}{dt} = gE - (r+d)I, \#(2.3)$$
$$\frac{dR}{dt} = rI, \#(2.4)$$
$$\frac{dD}{dt} = dI, \#(2.5)$$

96 where S, E, I, R, and D indicate the populations of susceptible, exposed, infectious, recovered, and dead

97 people, respectively; *N* indicates the total population, that is, N=S+E+I+R; *b* indicates the exposure rate, 98 which reflects the level of social activity; and *g*, *r*, and *d* indicate the transition rates among the 99 subpopulations. In this model, the recovered population is assumed to acquire permanent immunity,

100 indicating that they will never be infected.

It is made available under a CC-BY-NC-ND 4.0 International license .



101

102 Figure 1: Schematic of the classical SEIRD and testing-SEIRD models

103 (A) Classical SEIRD model: An infectious population "T" exposes a susceptible population "S" at a rate inversely 104 proportional to the infectious population. The exposed population "E" becomes infectious "I." The infected population 105 finally recovers "R" or is dead "D." (B) Testing-SEIRD model: The population is divided into two subpopulations; 106 inside and outside the hospital. The exposed "E_o" and the infectious population outside "I_o" are hospitalized if evaluated 107 as positive after testing. A susceptible population "S_h" remains at the hospitals. The black lines indicate population 108 transitions, regardless of the capacity effect. The blue lines indicate population transition, considering the capacity 109 effect. Transitions from "E_o" to "E_h" and "I_o" to "I_h" are categorized as hospitalized.

110

111 To incorporate the testing characteristics and testing strategies into the classical SEIRD model, we 112 divided the population into outside and inside of the hospital (Fig. 1B). The dynamics of the population 113 outside the hospitals are described using the following:

It is made available under a CC-BY-NC-ND 4.0 International license .

$$\frac{dI_o}{dt} = gE_o - (r_o + d_o)I_o - mSeI_oH(C - N_h), \#(2.8)$$
$$\frac{dR_o}{dt} = r_oI_o, \#(2.9)$$
$$\frac{dD_o}{dt} = d_oI_o, \#(2.10)$$

and those inside hospitals are described using the following:

10

$$\frac{dS_h}{dt} = -\frac{bI_h S_h}{N_h} + uE_h + aS_h, \#(2.11)$$

$$\frac{dE_h}{dt} = \frac{bI_h S_h}{N_h} - (u+g)E_h + f(1-Sp)E_oH(C-N_h), \#(2.12)$$

$$\frac{dI_h}{dt} = gE_h - (r_h + d_h)I_h + mSeI_oH(C-N_h), \#(2.13)$$

$$\frac{dR_h}{dt} = r_hI_h, \#(2.14)$$

$$\frac{dD_h}{dt} = d_hI_h, \#(2.15)$$

115 where X_{a} and X_{b} indicate each population outside and inside the hospital ($X \in \{S, E, I, R, D, N\}$), respectively;

116 N_o and N_h indicate the total populations outside and inside hospitals, respectively (that is, $N_o = S_o + E_o + I_o + R_o + R_o$

and $N_n = S_n + E_n + I_n$; *a* indicates the rate of discharge of S_n from the hospital to the outside; *u* and *g* indicate the

non-infection and infection rates, respectively; C indicates the capacity of hospitals. We assumed that the nature of the disease would determine these parameters; making them independent of hospitals both inside

and outside. r_i and d_i ($i \in \{o, h\}$) indicate the recovery and death rates from infection, respectively, where $r_i < 1$

 r_{a} , and $d_{a} < d_{a}$; *f* and *m* indicate the rates of follow-up and mass-testing, corresponding to the extent to which health centers follow exposed populations and take-up infected populations having symptoms, respectively; Sp and Se indicate specificity and sensitivity, respectively, as testing characteristics. The model assumed that

124 I has a fixed proportion of symptomatic and asymptomatic individuals, and that symptomatic infected

125 individuals receive mass-testing. The sigmoid function $H(x) = 1/(1 + \exp(x))$ introduced the hospitalization

126 capacity. The parameter values and initial conditions are listed in Table 1 and discussed in the Materials and

- 127 Methods section.
- 128

It is made available under a CC-BY-NC-ND 4.0 International license .

А		С							
Variab	le Value	Reference	Model	b	g	Гh	ro	dh	do
Sh,Eh,	In 1	Fang ²⁸	eSEIR	0.9 e-5 to e-6†	0.143	0.056	n/a	n/a	n/a
lo.	97	Tang ²⁹	n/a	2.1 e-8	0.126	n/a	0.14	1.78 e-5	n/a
S0	999900	Kucharski ³⁰	eSEIR	n/a	0.156	n/a	n/a	n/a	n/a
Eo,Rh,Ro,L	Dh,Do 0	Backer ³¹	n/a	n/a	0.143 to 0.33	n/a	n/a	n/a	n/a
		Bi Q ³²	n/a	n/a	n/a	n/a	n/a	n/a	n/a
		Kuniya ³³	SEIR	0.2 e-8†	n/a	n/a	n/a	n/a	n/a
Parame	ter Value	Linton ³⁴	n/a	n/a	0.2	n/a	n/a	n/a	n/a
Se	0.7	- Iwata ³⁶	SEIR	n/a	0.167 to 0.208	0.13 to 0.417	n/a	n/a	n/a
Sp	0.7	Sun ³⁷	vSIR	n/a	n/a	0.1	n/a	n/a	n/a
f	0.05	Pocklöv ³⁸	SEIR	0 4 e 4 or 0 12 e 4t	0.2	n/a	n/a	n/a	n/a
m	0.01	- 48		0.4 0-4 01 0.12 0-41	0.2	n/a	n/a	in a	n/u
b	1	Roda*°	SIR/SEIR	8.68 e-8	0.631	0.1	n/a	n/a	n/a
u	0.04								
g	0.16								
n ro	0.093			D	Reference	Incubation period		Infectious period	
dh.	0.090				Kucharski ³⁰	5.2		2.9	
do	0.01				Backer ³¹	6.5		n/a	
					Bi Q ³²	4.8		1.5	
Р					Wu ³⁵	6.1		2.3	
D	Mode of test	Se	Sp	_	Docklöv ³⁸	5		10	
	CT 0.98 ²⁸	0.98 ²⁸ , 0.97 ^{57,59} ,	0 828 to 0 9660)	RUCKIOV	5		10	
		0.8 to 0.9 ⁵⁰ ,0.972 ⁶¹			Lin ⁴⁷	5.2		2.3	
	PCR	0.71 ²⁸ ,0.846 ⁶¹	n/a	WH	IO-China Joint49	5.5		n/a	

129

130 Table 1: Variables and parameters in reports during the early stages of the pandemic

(A) Initial values for variables and parameters, (B) Reported sensitivity and specificity of the polymerase chain
reaction (PCR) and CT for detecting COVID-19, Cells expressed as n/a indicate that we could not find the (C) reported
transition parameters using models. Values with † are calculated from the original values for comparison. All values
have a [one/day] dimension. We could not find values or models for the cells expressed as n/a. The values with † equal
original values are divided by the total population, and (D) Reported incubation period and infectious periods. Each
value has a [day] dimension.

It is made available under a CC-BY-NC-ND 4.0 International license .

138 **3 Results**

153

139 First, we examined the basic behavior of the testing-SEIRD model using simulations, as shown in Fig. 2. 140 Similar to the classical SEIRD model, the infection primarily expands, and infectious populations (I_{h} and I_{o}) 141 transiently increase in response to the presence of infectious people. Susceptible populations (S_b and S_o) 142 gradually decrease and change into recovered populations (R_{b} and R_{c}) through the exposed (E_{b} and E_{c}) and 143 infectious (I_{b} and I_{b}) states. During this process, the number of dead people increases gradually, as shown in 144 Fig. 2A. Because of hospital overcrowding, the outside and hospitalized populations decrease and increase in 145response to testing, respectively, and their time courses are affected (Fig. 2B). The outside and hospitalized 146 populations are divided into five types of populations (susceptible, exposed, infectious, recovered, and dead) 147 (Figs. 2C and 2D). According to Fig. 2E, daily reports of positive tests and deaths transiently increase with 148 different peak timings, and the peak of positive tests precedes that of deaths. 149 To evaluate the speed of an infectious outbreak, we computed the basic reproduction number RN, 150 which is the expected number of infections caused by one infected person until recovery (see Materials and

when is the expected number of infections caused by one infected person until fectivery (see waterials and

151 Methods). Reproduction numbers outside hospitals, RN_a switches from greater than one to less than one 152 around the peak timing of infectious populations outside (Fig. 2F). Conversely, reproduction numbers inside

154 hospitals increases owing to outside factors rather than an infectious spread within the hospitals. The testing-

hospitals, RN_{k} are less than one around the peak timing. This indicates that the infectious population in

155 SEIRD model recapitulates the basic infection dynamics of the total population as observed in the classical

156 SEIRD model (Fig. 2A) and enables us to examine the effect of the testing strategy and testing

157 characteristics with different populations inside and outside hospitals.

It is made available under a CC-BY-NC-ND 4.0 International license .



158

159 Figure 2: Changes in components over time in the testing-SEIRD model

Time-courses of (A) populations of all infectious states, irrespective of being inside and outside hospitals; (B) populations inside and outside hospitals and dead populations, irrespective of infectious states; (C) populations of all infectious states inside hospitals; (D) populations of all infectious states outside hospitals; (E) Daily reports of positive test results, hospitalizations, and deaths; and (F) Time-courses of reproduction numbers inside and outside hospitals, as described in Materials and Methods section.

165

To investigate the impact of hospitalization capacity on infection dynamics, such as daily reports of positive test results, hospitalizations, and deaths, we simulated the testing-SEIRD model with various capacities (Figs. 3A–3C). The results demonstrate that as the capacity increases, the maximum positive tests,

It is made available under a CC-BY-NC-ND 4.0 International license .

169 maximum hospitalizations, and cumulative deaths linearly decrease, increase, and decrease, respectively.

170 They all plateau at approximately 30% capacity (Figs. 3D-3F), and notches are observed to reflect the

171 capacity effect (Figs. 3B, 3D, 3E, 3F, 3G, 3H, and 3I). Additionally, we examined their peak timings and

- found that they changed nonlinearly within certain time window ranges (Figs. 3G–3I). These results suggest
- that the capacity change has a significant effect on the disease's rate of spread but only a minor effect on
- 174 timing.
- 175



176



178 Time courses of (A) Daily reports of positive test results. (B) Daily reports of hospitalizations. (C) Daily reports of

179 deaths with varying hospitalization capacity. C/N indicates the capacity normalized to the total population.

180 Hospitalization capacity dependencies of (D) Maximum-positive reports. (E) Maximum hospitalizations. (F)

181 Cumulative deaths. Hospitalization capacity-dependencies of (G) Peak of daily reports of positive tests. (H) Peak of

182 hospitalizations. (I) Peak of daily deaths.

183

To illustrate the impact of the testing strategy on infectious outcomes, we examined the cumulative deaths, maximum number of positive tests and hospitalizations, varying follow-up, and mass-testing rates. The infectious spread shows an all-or-none response depending on the testing strategy (red and blue regions in Fig. 4). Sensitivity analyses demonstrated the robust maintenance of such a profile regardless of the model parameters (Figs. S1 and S2). The number of cumulative deaths was almost constant with a small amount of both the follow-up and mass-testing (red region in panels in the first row of Fig. 4A); however, the combination of follow-up and mass-testing successfully suppressed the infectious disease spread (blue region

It is made available under a CC-BY-NC-ND 4.0 International license .

191 in the panels in the first row of Fig. 4A). Furthermore, the maximum number of hospitalizations was 192 immediately saturated by either the follow-up or mass-testing because of the limited hospitalization capacity 193 (panels in the first row in Fig. 4B). The maximum number of positive tests increased more quickly with 194 follow-up testing compared with mass-testing (panels in the first row in Fig. 4C). According to statistics, the 195 number of cumulative deaths varied significantly depending on the strategies; there was a 724-fold 196 difference between the 90596 and 125 deaths at the optimal and worst strategies with a 1:1 cost ratio for 197 follow-up to mass-testing. Other infectious outcomes also depend on the strategies: there was a 466-fold 198 difference between 49424 and 106 hospitalizations and a 250-fold difference between 96525 and 135 daily 199 positive tests with the same cost ratio.

Subsequently, realistic scenarios were considered adapting to the limited resource L. Practically, the follow-up and mass-testing rates cannot be controlled because of the limited medical resources for both follow-up and mass-testing. Therefore, it is necessary to determine the amount of resources allocated to the follow-up and mass-testing. Here, we consider all the possible decisions subject to the limited resource L as follows:

$L = c_f f + c_m m, \#(3.1)$

205 where c_i and c_n indicate the costs for follow-up and mass-testing, respectively; f and m indicate the extent of 206 follow-up and mass-testing. We illustrated three lines using various L, c_{ρ} and c_{m} , based on the disease, 207 economic, and technological situations of each country (panels in the first row of Fig. 4). The three colored lines in the heat maps correspond to settings that are L=500, $c_f=1$, and $c_m=10$ in the green line; L=300, $c_f=1$, 208 209 and $c_m = 5$ in the blue line; and L=100, $c_f = 1$, and $c_m = 1$ in the orange line, respectively. Given the total amount of resources, we selected the optimal testing strategy on the line represented by Equation (3.1). We 210 211 demonstrated that the worst decisions (that is, the choice of f and m) significantly varied depending on the 212 situation (panels in the last row of Fig. 4).

213 Regarding the high resources and low ratio of the cost of follow-up testing to that of the mass-testing 214 cost, the number of cumulative deaths abruptly increases as the resource fraction of mass-testing exceeds 90% (green line in Fig. 4A). This indicates that the mass-dominant testing is the worst strategy for 215216minimizing the cumulative deaths. Conversely, the number of cumulative deaths abruptly decreases at the 217 resource fraction of 20-30% (blue line in Fig. 4A) assigned to mass-testing owing to low resource 218 availability and a high ratio of follow-up to mass-testing costs. Contrary to the previous case, this result 219 suggests that follow-up-dominant testing is the worst strategy. Regarding the intermediate situation between 220 the two cases above, the simulation showed a U-shape with the resource fraction assigned to mass-testing 221 ranging from approximately 10–80% (orange line in Fig. 4A). These results suggest that both follow-up and 222 mass-dominant testing strategies should be avoided. The choice of f and m also changed in the profiles of 223 maximum hospitalizations and positive reports (Figs. 4B and 4C). The optimal strategy for each 224 country/region depends on resource availability.

It is made available under a CC-BY-NC-ND 4.0 International license .



225

226 Figure 4: Infectious spread based on the testing strategy

The panels in the first row represent the number of (A) cumulative deaths, (B) maximum hospitalizations, and (C) maximum daily positive tests depending on the rates of follow-up and mass-testing. The three lines in these heatmaps represent the possible testing strategies subject to different total resources for testing with different ratios for the testing costs. *L*=500, c_f =1, and c_m =10 in the green line; *L*=300, c_f =1, and c_m =5 in the blue line; and *L*=100, c_f =1, and c_m =1 in the orange line. The panels in the second row represent the numbers along the three lines in the heatmaps. The panels in the third row represent semilog-plots of the second row.

233

234Moreover, we examined the effects of the testing characteristics (that is, sensitivity and specificity) 235 on the three variables (that is, the number of cumulative deaths, hospitalizations, and positive tests). We 236 conducted sensitivity analyses for Se and Sp using values ranging from zero to four in 0.01 increments. We 237 obtained almost the same heatmaps in the sensitivity-specificity space although the heatmaps were inverted 238 along the x-axis (Fig. 5). The Equations (2.7), (2.8), (2.12), and (2.13) reveal that sensitivity and one-239 specificity essentially play the same roles in the follow-up and mass-testing. The sensitivity and specificity 240 of the test cannot be changed, whereas the testing strategy can be arbitrary. If the sensitivity is low, an 241 increase in the mass-testing rate can produce the same infectious result with high sensitivity. Conversely, if 242 the specificity is low, a decrease in the follow-up testing rate can produce the same infectious result with 243 high specificity. Therefore, we must manage the optimal testing strategy based on the testing sensitivity and 244 specificity that cannot be changed.

It is made available under a CC-BY-NC-ND 4.0 International license .





Figure 5: Infectious spread based on the testing properties

Numbers of (A) Cumulative deaths, (B) Maximum hospitalizations, and (C) Maximum daily positive tests based on the
 sensitivity and specificity of the testing.

249

250 We investigated how the infection is spread based on the testing strategy. However, this is from the 251viewpoint of a perfect observer who knows the exact timeline of the latent populations. Practically, we were 252 unable to determine all the model variables, such as the exposed and infectious populations inside and outside hospitals; however, we could merely monitor positive reports by follow-up and mass-testing. In this 253 254study, we verified whether these two types of positive reports reflect the latent infectious population, which 255 is the most resource-consuming and challenging social issue. Using regression analysis (see Materials and 256Methods), we demonstrate that latent infectious populations can be predicted from daily positive reports of 257follow-up and mass-testing (Figs. 6A–6C). These results suggest that the infectious population is not only 258proportional to the total number of follow-up and mass-testing positive results but also proportional to their 259 weighted sum (Fig. 6D). There are some situations where weights can be negative, depending on the model 260 parameters. We found that follow-up testing's weight for positive reports was negative with high positive 261predictive values. This is because the negative weight of P_{c} represess the estimates of the latent number of 262 infectious people, reflecting a low positive predictive value (Fig. 6D).

It is made available under a CC-BY-NC-ND 4.0 International license .



263

264 Figure 6: Prediction of infectious population from daily reports of positive test results

(A-C) The Green and orange lines indicate the simulated and predicted infectious populations (I_h and I_o) with different testing strategies. The linear regression *as* $w_f P_f + w_m P_m$, where w_f and w_m indicate the weights and P_f and P_m indicate the daily positive reports of follow-up and mass-testing, namely, *f* (*1-Sp*) and *mSe*, respectively, was used to estimate the infectious populations. The least square method was used to estimate the weights. (D) The estimated weights for P_f and P_m are plotted, considering various combinations of ratios of the follow-up cost to the mass-testing cost (P_f/P_m).

270

It is made available under a CC-BY-NC-ND 4.0 International license .

272 **4 Discussion**

273 *Conclusion*

274 We developed a testing-SEIRD model with two discrete populations inside and outside hospitals, the 275impact of testing strategy (follow-up testing [f], and mass-testing [m]), and testing characteristics (sensitivity 276 [Se] and specificity [Sp]) on three important variables (the number of maximum positive tests, maximum 277 hospitalizations, and cumulative deaths (Fig. 1)). By simulating the model with parameters representing the 278 early stages of the COVID-19 Alpha variant pandemic, we demonstrated that the optimal and the worst 279testing strategies are subject to limited medical resources (Fig. 4). Additionally, we highlighted the 280 possibility that the infectious population can be predicted by a weighted sum of positive follow-up and mass-281 testing reports (Fig. 6).

282

283 **4-1** *Related work*

284 Infectious dynamics models, such as SEIRD models and their alternatives, which have been widely 285 used for policy making through model simulation, are abundant [1,26-46]. Although some of the previous 286 models included a hospital compartment [1,26-28,30,34], they did not consider the testing strategy and 287 testing characteristics. Our model assumes that in certain models, the exposed people do not infect the 288 susceptible ones but they end up being affected [1,26-38]. All models, except the model with intervention 289 strategies, [39] did not consider the testing cost. Similar to our model, three studies modeled the control of 290 infectious outbreaks, which addressed the possibility of an optimal solution for controlling infectious 291 outbreaks [39], the stable situation depending on the proportion of the susceptible population [40], and the 292 basic reproduction number depending on contact rate [43]. However, to the best of our knowledge, no model 293 has been developed that considers the effects of both testing characteristics and limited medical resources on 294the number of deaths. Consequently, our testing-SEIRD model introduced new factors: the hospital 295compartment, testing strategy, testing characteristics, and medical resources, compared with the previous 296 SEIRD model (Figs. 2-4). The testing-SEIRD model also comprehensively encompasses the classical 297 SEIRD model, which corresponds to the condition where f and m are both zero.

298

299 **4-2** *Model prediction*

Our model has three advantages. First, the testing-SEIRD model provides the optimal testing strategy for various situations. The model provides heatmaps based on the three variables' numbers in the space of the testing strategy (Fig. 4). These heatmaps indicate the best direction, which is shown by the blue region in Fig. 4. This corresponds to the settling of infections using the shortest path. Second, the testing-SEIRD model can predict the optimal and worst strategies, considering the limited medical resources and ratios for the testing costs (Fig. 4). Because the total costs of medical resources and testing depend on the

It is made available under a CC-BY-NC-ND 4.0 International license .

country, our model provides an optimal testing strategy unique to each country. Third, the testing-SEIRD
 model demonstrates that the latent number of infectious populations can be predicted from daily positive
 reports of the follow-up and mass-testing (Fig. 6).

309

4-3 Validity of the model components

311 Here, we discuss the validity of the model components, which is not factored by the previous models. First, we focus on the transition from E_{\circ} to E_{h} (Fig. 1). We assume that the follow-up testing causes the 312 313 hospitalization of the exposed population. Populations who have only recently been exposed but have not yet 314 developed symptoms do not participate in the tests. They only test when the follow-up encourages them. 315 Second, in relation to the transition from I_{a} to I_{b} , we assume that the mass-testing causes the hospitalizations 316 of the infectious population, which is defined as a person with symptoms. In our model, we address the rate 317 of mass-testing as a modifiable parameter because the rate depends on the volume of tests, such as PCR and 318 the degree of social penalty if it is positive. Third, we consider the transition from E_a to S_a and E_b to S_b . In our 319 model, all the exposed populations are not necessarily infected and some return susceptible compared with 320 the previous models, which assume that all exposed populations are destined to be infected [28,30,32,33,35-321 38,47-49]. Consistent with our model, some exposed populations return to susceptible populations without 322 developing symptoms. Finally, because the above-mentioned assumptions regarding exposure, infection, and 323 hospitalization processes are common in VOCs, our model is not specific to the Alpha variant but is 324 applicable to other VOCs [8]. Combining new components and the testing-SEIRD model is consistent with 325 the previous simulation model and reflects and incorporates a practical viewpoint.

326

327 **4-4** Validity of the model parameters

328 We used parameters from earlier reports before the Beta variant emerged in South Africa in May 2020 [8] (Table 1) because the earlier reports contained homogeneous Alpha variant data. After May 2020, 329 330 the reports present an inhomogeneous mixture of multiple variants. A sensitivity analysis was performed 331 after setting the sensitivity and specificity of testing to 0.7 each, as shown in (Fig. 4). The results were 332 robustly guaranteed. The incubation and infectious periods remained roughly stable in VOCs, while the 333 number of reproductions and mortality rates differed among variants [8,12,14]. A sensitivity analysis of b 334 and u provided a robust guarantee for the number of reproductions and reinfections [42] effects (Fig. S1). 335 Mortality was considered in the model with d_a and d_b and these values were sensitivity analyzed (Fig. S2). A 336 sensitivity analysis robustly guaranteed a or the rate of discharge from S₄ (Fig. S3). Although these values 337 are based on the COVID-19 Alpha variant, our sensitivity analysis indicates that the testing-SEIRD model 338 robustly generated the optimal and worst testing strategies for other VOCs with different parameters.

Our model does not assign a specific value to the basic reproduction number even though it is one of the most crucial variables in infectious diseases [39,51,52]. Instead, it is only obtained using Equations (5.1)

It is made available under a CC-BY-NC-ND 4.0 International license .

to (5.3). This is permissive because the reproduction number depends on the exposure rate (*b*) [43], and we performed a sensitivity analysis for the value of *b* (Fig. S1).

343

344 **4-5** *Future studies*

345Considering the future perspectives of our model, first, our testing-SEIRD model only simulates an 346 infection's single peak time course. However, we observed several COVID-19 infection peaks in many 347 countries [53]. To incorporate the multiple peaked dynamics, we must introduce the socio-psychological 348 effects caused by policies such as lockdown and social distancing. Second, our model assumes that all 349 populations are homogeneous and does not address stratification based on attributes such as gender, age, 350 social activities, and comorbidities [54,55]. Future research should consider this perspective. Finally, our 351 model did not include the effects of vaccination. There are current efforts to fight the spread of COVID-19 352 using messenger RNA (mRNA) vaccines. Our results appear favorable; however, we do not know the 353 duration of the effect of the vaccinations or the effectiveness of the acquired immunity against VOCs 354[53,56,57]. Therefore, the tug-of-war between the evolution of vaccines and the spread of virus remains 355 elusive.

It is made available under a CC-BY-NC-ND 4.0 International license .

5 Materials and Methods

358 **5-1** *Parameter set*

359 The parameters and initial conditions of the simulation are listed in Table 1A. We used parameters 360 from the COVID-19 Alpha variant studies. The total population N was set to 1,000,000 according to the 361 United Nations statistical papers: The World's Cities in 2018 states that one in five people worldwide live in 362 a city with more than one million inhabitants, and the median value of inhabitants is between 500,000 and 363 one million [58]. Therefore, sensitivity Se and specificity Sp were both set to 0.7, corresponding to those of 364 the PCR for detecting COVID-19 (Table 1B) [28,47,58-61]. The values of b, g, r_h , r_o , and d_h are based on previous reports (Table 1C) [3,29–34,36–38,50]. The sum of u and g is the inverse of the incubation period 365 366 during the exposed state, which is reportedly five days (Table 1C) [31-33,49,60]. The sum of r and d is the 367 inverse of the infectious period during the infectious state, which is reportedly ten days (Table 1D) 368 [31,32,35,60].

369

370 **5-2** Definitions of reproduction numbers

371 We computed the time courses of the reproduction numbers inside and outside hospitals (RN_h and 372 RN_o) using Fig. 2.

$$RN_{h} = \frac{1}{r_{h} + d_{h}} \cdot \frac{bS_{h}}{S_{h} + E_{h} + I_{h}} \cdot \frac{g}{u + g}, \#(5.1)$$
$$RN_{o} = \frac{1}{r_{o} + d_{o}} \cdot \frac{bS_{o}}{S_{o} + E_{o} + I_{o} + R_{o} + R_{h}} \cdot \frac{g}{u + g}. \#(5.2)$$

Here, the first, second, and third factors in these equations indicate the average infectious period, infection rate, and probability that the exposed state transits to the infectious state, respectively. The reproduction number in the classical SEIRD model was defined in previous studies [1,27–34] as follows:

$$RN = \frac{1}{r+d} \cdot \frac{bS}{S+E+I+R} \cdot \#(5.3)$$

376

377 5-3 Code and data availability

All codes and data required to reproduce the results of this study are hosted in Github at <u>https://github.com/bougtoir/testing-SEIRD</u>. The Github repository contains Jupyter notebooks for Runge-Kutta method differential equations and their visualization. The python codes described in the Jupyter notebooks can reproduce all figures in this study without the need for external files or settings.

382

It is made available under a CC-BY-NC-ND 4.0 International license .

384 Acknowledgments

385 We thank Tomohiko Takada M.D. (Ph.D.) and Yoshika Onishi M.D. (Ph.D.) for providing the basic concepts of

- clinical NNT. We thank Yoshiaki Yamagishi M.D. (Ph.D.), Tomokazu Doi M.D. (Ph.D.), and Tatsuyoshi Ikenoue
- 387 M.D. (Ph.D.) for revising the early manuscript. We also acknowledge Prof. Hiroshi Nishiura for organizing a
- summer boot camp in 2014 to provide fundamental knowledge on infectious disease modeling.

389

390 Funding

391 This study was partly supported by the Cooperative Study Program of Exploratory Research Centre on Life and

- 392 Living Systems (ExCELLS) (program Nos.18-201, 19-102, and 19-202 to H.N.), a Grant-in-Aid for
- 393 Transformative Research Areas (B) [grant number 21H05170], and a Grant-in-Aid for Scientific Research (B)
- 394 (21H03541 to H.N.) from the Japan Society for the Promotion of Science (JSPS).
- 395

396 Ethics

397 This study did not involve human or animal subjects.

398

399 Author Contributions

400 O.T. and Y.I. conceived the initial ideas. O.T. developed and implemented the method, processed, and analyzed 401 the data, and wrote the initial draft of the manuscript. H.N. revised the initial draft of the manuscript and reviewed 402 the method. Y.I. supervised the project. All authors contributed to the final writing of the manuscript.

403

404 **Competing Interests**

405 The authors declare no competing interests.

It is made available under a CC-BY-NC-ND 4.0 International license .

407 **References**

409	1.	Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R COVID-19 infection: Origin, transmission,
410		and characteristics of human coronaviruses. 2020;24:,91-98. doi:10.1016/j.jare.2020.03.005
411	2.	Kolifarhood G, Aghaali M, Saadati HM, Taherpour N, Rahimi S, Izadi N, Saeed S, Nazari H
412		Epidemiological and Clinical Aspects of COVID-19; a Narrative Review. 2020;8,41.
413		doi:10.22037/AAEM.V8I1.620
414	3.	Johns Hopkins Coronavirus Resource Center. COVID-19 Map In [Internet] Johns Hopkins
415		Coronavirus Resource Center; [cited 21May.2020]. Available:
416		https://coronavirus.jhu.edu/map.html
417	4.	GitHub - owid/covid-19-data: Data on COVID-19 (coronavirus) cases, deaths, hospitalizations,
418		tests • All countries • Updated daily by Our World in Data. In: [Internet]. Our world in Data ; [cited
419		31March.2022] Available: https://github.com/owid/covid-19-data
420	5.	2021 COVID Data Tracker, Centers for Disease Control and Prevention. In: [Internet]. Centers for
421		Disease Control and Prevention. [cited 31March.2022] Available: https://covid.cdc.gov/covid-data-
422		tracker/#datatracker-home
423	6.	Coronavirus disease 2019 (COVID-19) Situation Report - 46 . In: [Internet]. World Health
424		Organization; [cited 31March.2022]. Available: https://www.un.org/unispal/document/coronavirus-
425		disease-2019-covid-19-situation-report-46/
426	7.	2020 Laboratory testing strategy recommendations for COVID-19. In: [Internet]. World Health
427		Organization; [cited 31March.2022]. Available:
428		https://apps.who.int/iris/bitstream/handle/10665/331509/WHO-COVID-19-lab_testing-2020.1-
429		eng.pdf.
430	8.	Tracking-SARS-CoV-2-variants. In: [Internet]. World Health Organization; [cited 31March.2022].
431		Available https://www.who.int/en/activities/tracking-SARS-CoV-2-variants
432	9.	Joebges S, Biller-Andorno N. Ethics guidelines on COVID-19 triage - An emerging international
433		consensus. 2020;24, 1-5. doi:10.1186/s13054-020-02927-1
434	10.	Yan Bai, MD Lingsheng Yao, MD TaoWei, MD Fei Tian, MD Dong-Yan Jin, PhD Lijuan Chen,
435		PhD MeiyunWang, MD P. Letters Presumed Asymptomatic Carrier Transmission of COVID-19.
436		2020;323(14): 1406-1407 doi:10.1001/jama.2020.2565
437	11.	Al-Sadeq DW, Nasrallah GK. The incidence of the novel coronavirus SARS-CoV-2 among
438		asymptomatic patients: A systematic review. 2020; 98, 372-380. doi:10.1016/j.ijid.2020.06.098
439	12.	Mallett S et al. At what times during infection is SARS- CoV-2 detectable and no longer
440		detectable using RT-PCR-based tests ? A systematic review of individual participant data.
441		2020;18, 1–17. doi:10.1186/s12916-020-01810-8
442	13.	Yukari C. Manabe M, Joshua S. Sharfstein M, Katrina Armstrong M. The Need for More and
443		Better Testing for COVID-19. 2020;324(21): 2153-2154. doi:10.1001/jama.2020.21694

14.	Rhee C, Kanjilal S, Baker M, Klompas M. Duration of Severe Acute Respiratory Syndrome
	Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue Isolation? 2021;72,
	1467–1474. doi:10.1093/cid/ciaa1249
15.	Wilson E, Donovan C V, Campbell M. Multiple COVID-19 Clusters on a University Campus -
	North Carolina, August 2020;69, 1416–1418. doi: 10.15585/mmwr.mm6939e3
16.	Id VB, Mallein B. Group testing as a strategy for COVID-19 epidemiological monitoring and
	community surveillance. 2021;17, 1–25. doi:10.1371/journal.pcbi.1008726
17.	Testing for COVID-19: A way to lift confinement restrictions. In: [Internet]. Organisation for
	Economic Cooperation and Development; [cited 31March.2022]. Available: https://read.oecd-
	ilibrary.org/view/?ref=129_129658-l62d7lr66u&title=Testing-for-COVID-19-A-way-to-lift-
	confinement-restrictions.
18.	Signorini SG, Brugnoni D. Less is more : an ecological and economic point of view on
	appropriate use of lab testing for COVID patients. 2021;24, 781-1783. doi:10.4155/bio-2021-0064
19.	Overview of testing for SARS-CoV-2 (COVID-19). In: [Internet]. Centers for Disease Control and
	Prevention; [cited 29August.2020]. Available: https://www.cdc.gov/coronavirus/2019-
	ncov/hcp/testing-overview.html
20.	Id DRB, Bish EK, El-hajj H, Aprahamian H. A robust pooled testing approach to expand COVID-
	19 screening capacity.2021;16(2), 1-15. doi:10.1371/journal.pone.0246285
21.	Thought on COVID-19 testing. In: [Internet]. Japanese society of pediatrics; [cited 21May.2020].
	Available: http://www.jpeds.or.jp/modules/activity/index.php?content_id=329
22.	WHO Director-General's opening remarks at the media briefing on COVID-19 - 16 March 2020.
	In: [Internet]. World Health Organization; [cited 21May.2020]. Available:
	https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-
	the-media-briefing-on-covid-1916-march-2020
23.	Godlee F. The burning building. 2020;368, m1101. doi:10.1136/bmj.m1101
24.	Peto J. Covid-19 mass testing facilities could end the epidemic rapidly. 2020; 368, m1163.
	doi:10.1136/bmj.m1163
25.	Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. In:
	[Internet]. World Health Organization; [cited 31March.2022]. Available:
	https://www.who.int/publications/i/item/10665-331501
26.	Gerardo C, Lisa S, Shweta B, Cécile V. Mathematical models to characterize early epidemic
	growth: A Review. 2018;176, 139–148. doi:10.1016/j.plrev.2016.07.005.Mathematical
27.	Roguski KM et al. Estimates of global seasonal influenza-associated respiratory mortality: a
	modelling study. 2019; 391, 1285-1300. doi:10.1016/S0140-6736(17)33293-2
28.	Fang Y, Nie Y, Penny M. Transmission dynamics of the COVID-19 outbreak and effectiveness of
	government interventions: A data-driven analysis. 2020;92(6), 645-659. doi:10.1002/jmv.25750
	 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28.

480	29.	Tang B, Bragazzi NL, Li Q, Tang S, Xiao Y, Wu J. An updated estimation of the risk of
481		transmission of the novel coronavirus (2019-nCov). 2020; 5, 248-255.
482		doi:10.1016/j.idm.2020.02.001
483	30.	Kucharski AJ et al. Early dynamics of transmission and control of COVID-19: a mathematical
484		modelling study. 2020; 20, 553-558. doi:10.1016/S1473-3099(20)30144-4
485	31.	Backer J, Klinkenberg D, Wallinga J. The incubation period of 2019-nCoV infections among
486		travellers from Wuhan, China. 2020;25(5):pii=2000062. doi:10.2807/1560-
487		7917.ES.2020.25.5.2000062
488	32.	Bi Q et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close
489		contacts in Shenzhen, China: a retrospective cohort study. 2020;20, 911-919. doi:10.1016/S1473-
490		3099(20)30287-5
491	33.	Kuniya T. Prediction of the Epidemic Peak of Coronavirus Disease in Japan, 2020. 2020;9(3).
492		doi:10.3390/jcm9030789
493	34.	Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung SM, Yuan B, Kinoshita R,
494		Nishiura H. Incubation period and other epidemiological characteristics of 2019 novel coronavirus
495		infections with right truncation: A statistical analysis of publicly available case data. 2020;9, 538.
496		doi:10.1101/2020.01.26.20018754
497	35.	Joseph TW, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and
498		international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study.
499		2020;395, 689–697. doi:10.1016/S0140-6736(20)30260-9
500	36.	Iwata K, Miyakoshi C. A Simulation on Potential Secondary Spread of Novel Coronavirus in an
501		Exported Country Using a Stochastic Epidemic SEIR Model. 2020;9, 944.
502		doi:10.3390/jcm9040944
503	37.	Sun H, Qiu Y, Yan H, Huang Y, Zhu Y, Gu J, Chen S. Tracking Reproductivity of COVID-19
504		Epidemic in China with Varying Coefficient SIR Model. 2021; B , 455–472.
505		doi:10.6339/jds.202007_18(3).0010
506	38.	Rocklöv J, Sjödin H, Wilder-Smith A. COVID-19 outbreak on the diamond princess cruise ship:
507		Estimating the epidemic potential and effectiveness of public health countermeasures. 2021;27, 1-
508		7. doi:10.1093/JTM/TAAA030
509	39.	Mondal J., Khajanchi S. Mathematical modeling and optimal intervention strategies of the
510		COVID-19 outbreak. 2022;109, 177-202. doi:10.1007/s11071-022-07235-7
511	40.	Khajanchi S., Sarkar K., Banerjee S. Modeling the dynamics of COVID-19 pandemic with
512		implementation of intervention strategies. 2022;137, 129. doi:10.1140/epjp/s13360-022-02347-w
513	41.	Tiwari, P. K., Rai, R. K., Khajanchi, S., Gupta, R. K., & Misra, A. K. Dynamics of coronavirus
514		pandemic: effects of community awareness and global information campaigns. 2021;136(10), 994.
515		doi:10.1140/epjp/s13360-021-01997-6

516	42.	Khajanchi, S., Sarkar, K., Mondal, J., Nisar, K. S., & Abdelwahab, S. F. Mathematical modeling of
517		the COVID-19 pandemic with intervention strategies. 2021;25, 104285.
518		doi:10.1016/j.rinp.2021.104285
519	43.	Sarkar, K., Khajanchi, S., & Nieto, J. J. Modeling and forecasting the COVID-19 pandemic in
520		India. 2020;139, 110049. doi:10.1016/j.chaos.2020.110049
521	44.	Khajanchi, S., & Sarkar, K. Forecasting the daily and cumulative number of cases for the COVID-
522		19 pandemic in India. 2020;30(7), 071101. doi:10.1063/5.0016240
523	45.	Samui, P., Mondal, J., & Khajanchi, S. A mathematical model for COVID-19 transmission
524		dynamics with a case study of India. 2020;140, 110173. doi:10.1016/j.chaos.2020.110173
525	46.	Rai, R. K., Khajanchi, S., Tiwari, P. K., Venturino, E., & Misra, A. K. Impact of social media
526		advertisements on the transmission dynamics of COVID-19 pandemic in India. 2022;68(1), 19-44.
527		doi:10.1007/s12190-021-01507-y
528	47.	Lin L et al. Using Artificial Intelligence to Detect COVID-19 and Community-acquired Pneumonia
529		Based on Pulmonary CT: Evaluation of the Diagnostic Accuracy. 2020;296(2), E65-E71.
530		doi:10.1148/radiol.2020200905
531	48.	Roda WC, Varughese MB, Han D, Li MY. Why is it difficult to accurately predict the COVID-19
532		epidemic? 2020;5, 271–281. doi:10.1016/j.idm.2020.03.001
533	49.	2020 China Joint Mission on Coronavirus Disease 2019 (COVID-19). World health organization.
534		2019, 16-24. In: [Internet]. World Health Organization; [cited 21May.2020]. Available
535		https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-
536		disease-2019-(covid-19)
537	50.	Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, Dushoff J,
538		Mlisana K, Moultrie H. Increased risk of SARS-CoV-2 reinfection associated with emergence of
539		Omicron in South Africa. Science 2022; 376, 1-43. doi:10.1126/science.abn4947
540	51.	Lu, X., Hui, L., Liu, S., & Li, J. A mathematical model of HTLV-I infection with two time delays.
541		2015;12(3), 431-449. doi:10.3934/mbe.2015.12.431
542	52.	Wang, L., Li, M. Y., & Kirschner, D. Mathematical analysis of the global dynamics of a model for
543		HTLV-I infection and ATL progression. 2002;179(2), 207-217. doi:10.1016/s0025-
544		5564(02)00103-7
545	53.	GISAID - Initiative. In: [Internet]. GISAID; [cited 9May.2021]. Available https://www.gisaid.org
546	54.	Shahid Z et al. COVID-19 and Older Adults: What We Know. 2020;68, 926–929.
547		doi:10.1111/jgs.16472
548	55.	Thomas DM, Sturdivant R, Dhurandhar N v., Debroy S, Clark N. A Primer on COVID-19
549		Mathematical Models. 2020;28, 1375-1377. doi:10.1002/oby.22881
550	56.	Sharp TM et al. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273
551		Vaccine for Covid-19. 2021; 384, 2257–2259. doi:10.1056/nejmc2023298
552	57.	Christian HH, Daniela M, Sophie MG, Kåre M, Steen E. Assessment of protection against
553		reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a

It is made available under a CC-BY-NC-ND 4.0 International license .

554		population-level observational study Christian. 2020;397(10280), 1204-1212. doi:10.1016/ S0140-
555		6736(21)00575-4
556	58.	United Nations. 2018 The World's Cities in 2018: Data Booklet. doi:10.18356/C93F4DC6-EN
557	59.	Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, Tao Q, Sun Z, Xia L. Correlation of Chest CT and
558		RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases.
559		2020;296(2), E32-E40200642. doi:10.1148/radiol.2020200642
560	60.	Long C et al. Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT?
561		2020;126,108961. doi:10.1016/j.erad.2020.108961
562	61.	Lai S et al. Effect of non-pharmaceutical interventions to contain COVID-19 in China. 2021;585,
563		410-413. doi:10.1038/s41586-020-2293-x.Effect
564		

It is made available under a CC-BY-NC-ND 4.0 International license .



567



569 Simulations were performed using different values of b and u.

It is made available under a CC-BY-NC-ND 4.0 International license .





- 573 Figure S2: Sensitivity analyses of d_o and d_h on the number of cumulative deaths
- 574 Simulations were performed using different values of d_o and d_h , where (d_o, d_h) of (0.01, 0.007) is a reference standard;
- 575 (0.01, 0.001) means advance in treatment; (0.01, 0.01) means futile treatment; and (0.001, 0.0007) means reduction in
- 576 overall mortality.

577



- 578 579 Figure S3: Sensitivity analyses of parameter *a* on the number of cumulative deaths
- 580 Simulations were performed using different values of parameter a.
- 581